000			01523 a2200409 4500
005			20250513194818.0
264		0	_c19991130
008			199911s 0 0 eng d
022			_a1784-3286
024	7		_a10.1080/17843286.1999.11754245 _2doi
040			_aNLM _beng _cNLM
100	1		_aRutgeerts, P
245	0	0	_aNew strategies in the management of inflammatory bowel disease. _h[electronic resource]
260			_bActa clinica Belgica _cOct 1999
300			_a274-80 p. _bdigital
500			_aPublication Type: Journal Article; Review
650	0	4	_aAdjuvants, Immunologic _xtherapeutic use
650	0	4	_aAnti-Inflammatory Agents, Non-Steroidal _xtherapeutic use
650	0	4	_aAntibodies, Monoclonal _xtherapeutic use
650	0	4	_aAzathioprine _xtherapeutic use
650	0	4	_aColitis, Ulcerative _xdrug therapy
650	0	4	_aCrohn Disease _xdrug therapy
650	0	4	_aCyclosporine _xtherapeutic use
650	0	4	_aGlucocorticoids _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aImmunity, Mucosal
650	0	4	_aImmunosuppressive Agents _xtherapeutic use
650	0	4	_aIncidence
650	0	4	_aInflammatory Bowel Diseases _xdrug therapy
650	0	4	_aInfliximab
650	0	4	_aMesalamine _xtherapeutic use
650	0	4	_aPrevalence
650	0	4	_aTumor Necrosis Factor-alpha _xantagonists & inhibitors
700	1		_aBaert, F
773	0		_tActa clinica Belgica _gvol. 54 _gno. 5 _gp. 274-80
856	4	0	_uhttps://doi.org/10.1080/17843286.1999.11754245 _zAvailable from publisher's website
999			_c10511960 _d10511960